Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Heme oxygenase-1–derived carbon monoxide enhances the host defense response to microbial sepsis in mice
Su Wol Chung, … , Rebecca M. Baron, Mark A. Perrella
Su Wol Chung, … , Rebecca M. Baron, Mark A. Perrella
Published December 3, 2007
Citation Information: J Clin Invest. 2008;118(1):239-247. https://doi.org/10.1172/JCI32730.
View: Text | PDF
Research Article Inflammation

Heme oxygenase-1–derived carbon monoxide enhances the host defense response to microbial sepsis in mice

  • Text
  • PDF
Abstract

Sepsis is characterized by a systemic response to severe infection. Although the inflammatory phase of sepsis helps eradicate the infection, it can have detrimental consequences if left unchecked. Therapy directed against inflammatory mediators of sepsis has shown little success and has the potential to impair innate antimicrobial defenses. Heme oxygenase-1 (HO-1) and the product of its enzymatic reaction, CO, have beneficial antiinflammatory properties, but little is known about their effects on microbial sepsis. Here, we have demonstrated that during microbial sepsis, HO-1–derived CO plays an important role in the antimicrobial process without inhibiting the inflammatory response. HO-1–deficient mice suffered exaggerated lethality from polymicrobial sepsis. Targeting HO-1 to SMCs and myofibroblasts of blood vessels and bowel ameliorated sepsis-induced death associated with Enterococcus faecalis, but not Escherichia coli, infection. The increase in HO-1 expression did not suppress circulating inflammatory cells or their accumulation at the site of injury but did enhance bacterial clearance by increasing phagocytosis and the endogenous antimicrobial response. Furthermore, injection of a CO-releasing molecule into WT mice increased phagocytosis and rescued HO-1–deficient mice from sepsis-induced lethality. These data advocate HO-1–derived CO as an important mediator of the host defense response to sepsis and suggest CO administration as a possible treatment for the disease.

Authors

Su Wol Chung, Xiaoli Liu, Alvaro A. Macias, Rebecca M. Baron, Mark A. Perrella

×

Figure 7

CO-RM rescues mice from the mortality of CLP-induced polymicrobial sepsis.

Options: View larger image (or click on image) Download as PowerPoint
CO-RM rescues mice from the mortality of CLP-induced polymicrobial sepsi...
(A) Treatment (Tx) with CO-RM (10 μM/kg, n = 8) or an equal volume of vehicle (12.5% DMSO in PBS, n = 8) was administered intraperitoneally to HO-1–/– mice 12 hours and 2 hours before and every 24 hours after CLP surgery (19 gauge, 1 hole). Survival rates were then assessed over the subsequent 8 days. P = 0.03. The data are a composite of 3 independent experiments. (B) Treatment with CO-RM (10 μM/kg, n = 14) or an equal volume of vehicle (n = 14) was administered intraperitoneally to HO-1+/+ mice starting 6 hours after CLP surgery (19 gauge, 2 holes), after 12 hours, and then every 24 hours. Survival rates were assessed over the subsequent 8 days. P = 0.04. Data are a composite of 5 independent experiments. Short arrows depict the time of CLP surgery, and the longer arrows represent the initiation of treatment, either CO-RM or vehicle.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts